YOU ARE HERE:
Changing treatments news
page  of 7
 
Headline
Date
  New EACS guidelines address co-morbidities and diseases of age
16.11.09
  Protease inhibitor monotherapy as a maintenance regimen: are we edging towards acceptance?
16.11.09
  Multiple treatment failures occur less frequently but remain associated with high mortality rates in North American cohort
06.11.09
  Dual maintenance therapy with atazanavir plus raltegravir sustains viral suppression
18.09.09
  Boosted protease inhibitor regimens with 3TC work despite M184V resistance
18.09.09
  Switches to second-line ART occurring faster where viral load testing available
15.09.09
  Delays in switching treatment: NRTI resistance can be slower to emerge than expected
08.09.09
  Boosted darunavir monotherapy works well in two studies
23.07.09
  Boosted and unboosted atazanavir maintain viral suppression equally well
23.07.09
  DART study shows HIV treatment without lab monitoring safe, effective in Africa
21.07.09
  Further evidence of needless treatment switches in absence of viral load testing
13.07.09
  Raltegravir aprobat in SUA pentru tratamentul HIV de prima linie
13.07.09
  Ritonavir-boosted atazanavir as protease-only maintenance therapy: 48-week results
12.03.09
  Switching from Kaletra to raltegravir improves lipid profiles at the risk of viral rebound
10.02.09
  Rare abacavir liver side-effects reported
02.12.08
  Second-line combinations fail twice as often as first-line ones in the first year
16.11.08
  If you can't switch, better to stay on failing treatment than stop it, studies show
14.11.08
  Darunavir European license extended to all treatment-experienced
30.10.08
  CD4 decline, death more likely if change from NNRTI regimen delayed
23.10.08
  Reduced dose atazanavir safe and effective in small Thai study
17.10.08

page  of 7